Table 1 Baseline characteristics of all acute stroke patients at inclusion and divided by whether they completed in-hospital follow-up or not
All (N = 911) | With follow-up (N = 661) | No follow-up (N = 251) | p-value2 | |
|---|---|---|---|---|
Male (sex) | 52 (57%) | 42 (64%) | 10 (40%) | 0.072 |
Age | 66 (11) | 66 (11) | 67 (12) | 0.855 |
BMI | 27.6 (6.0) | 27.3 (5.2) | 28.4 (7.9) | 0.943 |
History of smoking | ||||
Current | 26 (29%) | 21 (32%) | 5 (20%) | 0.514 |
Ex. Smoker | 34 (37%) | 23 (35%) | 11 (44%) | |
Never-smoker | 31 (34%) | 22 (33%) | 9 (36%) | |
Baseline mRS | 2 (1, 3) | 2 (1, 3) | 2 (1, 4) | 0.403 |
Baseline NIHSS | 2 (1, 4) | 2 (1, 4) | 2 (1, 3) | 0.945 |
Lesion site | ||||
Insula | 9 (13%) | 6 (12%) | 3 (17%) | 0.693 |
Brainstem | 9 (14%) | 8 (16%) | 1 (5.9%) | 0.427 |
TOAST | ||||
Cardioembolic | 13 (14%) | 9 (14%) | 4 (16%) | 0.708 |
Large artery occlusion | 10 (11%) | 6 (9%) | 4 (16%) | |
Small vessel occlusion | 23 (25%) | 19 (29%) | 4 (16%) | |
Other etiology | 1 (1%) | 1 (2%) | 0 (0%) | |
Undetermined etiology | 44 (48%) | 31 (47%) | 13 (52%) | |
Total SVD score | ||||
0 | 26 (32%) | 18 (30%) | 8 (38%) | 0.796 |
1 | 17 (21%) | 12 (20%) | 5 (24%) | |
2 | 18 (22%) | 14 (23%) | 4 (19%) | |
3 | 18 (22%) | 15 (25%) | 3 (14%) | |
4 | 3 (3.7%) | 2 (3.3%) | 1 (4.8%) | |
Missing | 9 | 5 | 4 | |
Internal carotid atherosclerosis | ||||
None | 13 (14%) | 11 (17%) | 2 (8%) | 0.768 |
Mild | 27 (30%) | 20 (30%) | 7 (28%) | |
Moderate | 34 (37%) | 23 (35%) | 11 (44%) | |
Severe | 12 (13%) | 9 (14%) | 3 (12%) | |
Comorbidities | ||||
Diabetes type I or II | 19 (21%) | 14 (21%) | 5 (20%) | > 0.999 |
Hypertension | 54 (59%) | 38 (58%) | 16 (64%) | 0.751 |
History of stroke | 15 (16%) | 10 (15%) | 5 (20%) | 0.546 |
History of MI | 10 (11%) | 8 (12%) | 2 (8%) | 0.721 |
Atrial fibrillation | 17 (19%) | 11 (17%) | 6 (24%) | 0.547 |
Migraine | 13 (14%) | 10 (15%) | 3 (12%) | > 0.999 |
Cancer | 6 (7%) | 5 (8%) | 1 (4%) | > 0.999 |
Medications | ||||
Beta blockers | 34 (37%) | 23 (35%) | 11 (44%) | 0.574 |
Calcium channel blockers | 22 (24%) | 17 (26%) | 5 (20%) | 0.765 |
RAS inhibitors | 35 (38%) | 25 (38%) | 10 (40%) | > 0.999 |
Statins | 65 (71%) | 47 (71%) | 18 (72%) | > 0.999 |